Diagnóstico ecográfico de la neoplasia prostática y su relación histológica / Ultrasound diagnosis of prostatic neoplasia and histological relationship

Introducción: El desarrollo de la tecnología con el ultrasonido transrectal ha permitido obtener imágenes diagnósticas de la glándula prostática; su interés deriva de la inmensa frecuencia de problemas clínicos, tanto benignos como malignos. El medio diagnóstico del cáncer de próstata se basa en una biopsia dirigida por ultrasonido transrectal en la mayoría de los casos. Objetivo: Determinar los hallazgos ultrasonográficos y su relación con estudios histopatológico en el diagnóstico de la neoplasia prostática, de los pacientes con sospecha, atendidos en la consulta de urooncología. Métodos: Se realizó un estudio descriptivo transversal en pacientes con sospecha clínica de cáncer prostático, procedentes del servicio de urología en el Hospital Celia Sánchez Manduley en el período comprendido entre julio de 2019 a julio de 2021; que acudieron a consulta con indicación de ultrasonido transrectal. El universo estuvo constituido por 105 pacientes. Se utilizaron criterios de inclusión y exclusión para la selección del universo, previo consentimiento informado de los pacientes. Las variables estudiadas fueron: edad, color de la piel, síntomas clínicos, hallazgos del ultrasonido transrectal, relación ecosonográfica- anatomopatológico. Resultados: Predominó el grupo de edad de 60 a 79 años, de la raza negra, con síntomas urinarios obstructivos bajos, con presencia del nódulo hipoecoico. Predominó la localización ultrasonográfica periférica, así como el adenocarcinoma prostático como hallazgos anatomopatológico encontrado a través de la biopsia. Conclusiones: Se demostró correlación ecográfica-histológica y anatomopatológica(AU)

Introduction: The development of transrectal ultrasound technology has made it possible to obtain diagnostic images of the prostate gland; its interest derives from the massive frequency of clinical problems, both benign and malignant. The diagnosis of prostate cancer is based on a transrectal ultrasound-guided biopsy in most cases. Objective: To determine the ultrasonographic findings and the how they relate with histopathological studies in the diagnosis of prostatic neoplasia in suspected patients treated in the uro-oncology clinic. Methods: A cross-sectional descriptive study was carried out in patients with clinical suspicion of prostate cancer, in the urology service at Celia Sánchez Manduley Hospital from July 2019 to July 2021; they attended the consultation with an indication for transrectal ultrasound. The universe consisted of 105 patients. Inclusion and exclusion criteria were used for the selection of the universe, with the prior informed consent of the patients. The variables studied were age, skin color, clinical symptoms, transrectal ultrasound findings, echosonographic-pathological relationship. Results: Predominance was observed of subjects from the age group of 60 to 79 years, black race, with lower obstructive urinary symptoms, and presence of hypoechoic nodule. Peripheral ultrasonographic location prevailed, as well as prostatic adenocarcinoma as pathological findings found through biopsy. Conclusions: Ultrasound-histological and pathological correlation was demonstrated(AU)

Hemoperitoneum after transperineal prostate biopsy / Hemoperitoneo tras biopsia prostática transperineal

Abstract Bleeding is the most common complication after a prostate biopsy, commonly self-limited. We describe a case of a patient who developed a hemoperitoneum after a transperineal prostate biopsy. A 65-year-old man with a history of prostate cancer diagnosed in 2016 by transurethral resection, with no further urologic control until 2020 when a rise in the serum prostate-specific antigen was diagnosed: 4.49 ng/ml. Pros tate digital rectal examination had no pathologic findings. Magnetic resonance imaging informed anequivocal lesion. A target transperineal fusion biopsy was performed, guided by ultrasound (US). Pre-surgical blood tests, including coagulogram, were normal. No immediate postoperative complications were recorded, and the patient was discharged. Hours later, he returned after a head concussion due to orthostatic hypotension and diffuse abdominal pain. Blood test showed a drop in hematocrit and hemoglobin values. Abdominal US and abdomi nopelvic computed tomography scan showed free intraperitoneal fluid and intraperitoneal hematic collection on top of the bladder of 104 × 86 mm with no active bleeding. The patient was admitted to intensive care unit due to persistent hypotension despite fluid restoration. He received a single-unit blood transfusion and had a good response to vasopressors. Abdominal pain decreased. He was finally discharged with stable hematocrit 48 hours after admission. Clinical management with no surgery or radiologic angio-embolization was required. We found no clear origin of the intraperitoneal bleeding, but we hypothesize that maybe the previous transurethral resection of the prostate made anatomical changes that facilitated blood passage to the abdominal cavity after puncture of branches from the inferior vesical artery.

Resumen La complicación más frecuente tras una biopsia prostática es el sangrado, generalmente autolimitado. Aquí describimos un caso de he moperitoneo secundario a dicho procedimiento. Hombre de 65 años con antecedentes de cáncer de próstata diagnosticado en 2016 por una resección transuretral de próstata, sin seguimiento urológico, consultó en 2020 por aumento del antígeno prostático específico: 4.49 ng/ml, asociado a tacto rectal normal y una resonancia multiparamétrica de próstata mostró una lesión indeterminada. Se realizó una biopsia prostática transperineal por fusión guiado por ecografía. Los análisis preoperatorios, incluido coagulograma, eran normales. No se registraron complicaciones intraquirúrgicas y se indicó el alta. Horas más tarde, consultó al hospital por hipotensión ortos tática y dolor abdominal difuso. Los análisis demostraron caída del hematocrito y hemoglobina. Una ecografía y posterior tomografía computada evidenciaron una colección supravesical de 104 × 86mm sin signos de sangrado activo. Se indicó internación en sala de cuidados intensivos debido a hipotensión refractaria a expansiones con requerimiento de vasopresores. Recibió una transfusión de glóbulos rojos. Por favorable evolución, 48 horas después del ingreso recibió el alta. En este caso, fue posible un manejo conservador, sin requerimiento de cirugía o embolización. Si bien no se encontró sitio exacto del sangrado, creemos que la resección transuretral previa podría haber generado cambios anatómicos que facilitaran el pasaje de sangre, posiblemente proveniente de ramas de la arteria vesical inferior a cavidad abdominal luego de la punción.

Routine Systematic Prostate Biopsies not Replaced by Magnetic Resonance Imaging-Targeted Biopsy

ABSTRACT Background: Multiparametric magnetic resonance imaging improves the performance of prostate cancer (PCa) diagnostics through a better selection of patients. Objectives: The aim of the study was to study the detection rate (DR) of systematic and targeted cognitive biopsies in a cohort with the previous negative systematic biopsies. A secondary objective was to describe the value of prostate-specific antigen density (PSAd) in the detection of clinically significant PCa (CSPCa). Methods: We designed a prospective, single-center, and comparative study to determine the DR of systematic and targeted cognitive biopsies. The clinical and pathological characteristics of each patient were described. Results: A total of 111 patients with Prostate Imaging Reporting and Data System lesions > 3 were included in the study. PCa was detected in 41.4% (46 of 111 patients); 42 (91.3%) were detected by systematic biopsy and 30 (65.2%) by targeted biopsy. CSPCa was detected in 26 (23.4%), 23 (88.5%) by systematic biopsy, and 21 (76.9%) by targeted biopsy. PSAd > 0.15 was directly associated with CSPCa. Conclusion: The detection of PCa by systematic biopsy in this series was higher than 80%; hence, its routine use should not be replaced by targeted biopsy, since it continues to be the cornerstone of the diagnosis in patients with prior negative biopsies.

Routine systematic prostate biopsies not replaced by magnetic resonance imaging-targeted biopsy.

Background: Multiparametric magnetic resonance imaging improves the performance of prostate cancer (PCa) diagnostics through a better selection of patients. Objectives: The aim of the study was to study the detection rate (DR) of systematic and targeted cognitive biopsies in a cohort with the previous negative systematic biopsies. A secondary objective was to describe the value of prostate-specific antigen density (PSAd) in the detection of clinically significant PCa (CSPCa). Methods: We designed a prospective, single-center, and comparative study to determine the DR of systematic and targeted cognitive biopsies. The clinical and pathological characteristics of each patient were described. Results: A total of 111 patients with Prostate Imaging Reporting and Data System lesions > 3 were included in the study. PCa was detected in 41.4% (46 of 111 patients); 42 (91.3%) were detected by systematic biopsy and 30 (65.2%) by targeted biopsy. CSPCa was detected in 26 (23.4%), 23 (88.5%) by systematic biopsy, and 21 (76.9%) by targeted biopsy. PSAd > 0.15 was directly associated with CSPCa. Conclusion: The detection of PCa by systematic biopsy in this series was higher than 80%; hence, its routine use should not be replaced by targeted biopsy, since it continues to be the cornerstone of the diagnosis in patients with prior negative biopsies.

Hemoperitoneum after transperineal prostate biopsy.

Bleeding is the most common complication after a prostate biopsy, commonly self-limited. We describe a case of a patient who developed a hemoperitoneum after a transperineal prostate biopsy. A 65-year-old man with a history of prostate cancer diagnosed in 2016 by transurethral resection, with no further urologic control until 2020 when a rise in the serum prostate-specific antigen was diagnosed: 4.49 ng/ml. Prostate digital rectal examination had no pathologic findings. Magnetic resonance imaging informed anequivocal lesion. A target transperineal fusion biopsy was performed, guided by ultrasound (US). Pre-surgical blood tests, including coagulogram, were normal. No immediate postoperative complications were recorded, and the patient was discharged. Hours later, he returned after a head concussion due to orthostatic hypotension and diffuse abdominal pain. Blood test showed a drop in hematocrit and hemoglobin values. Abdominal US and abdominopelvic computed tomography scan showed free intraperitoneal fluid and intraperitoneal hematic collection on top of the bladder of 104 × 86 mm with no active bleeding. The patient was admitted to intensive care unit due to persistent hypotension despite fluid restoration. He received a single-unit blood transfusion and had a good response to vasopressors. Abdominal pain decreased. He was finally discharged with stable hematocrit 48hours after admission. Clinical management with no surgery or radiologic angio-embolization was required. We found no clear origin of the intraperitoneal bleeding, but we hypothesize that maybe the previous transurethral resection of the prostate made anatomical changes that facilitated blood passage to the abdominal cavity after puncture of branches from the inferior vesical artery.

La complicación más frecuente tras una biopsia prostática es el sangrado, generalmente autolimitado. Aquí describimos un caso de hemoperitoneo secundario a dicho procedimiento. Hombre de 65 años con antecedentes de cáncer de próstata diagnosticado en 2016 por una resección transuretral de próstata, sin seguimiento urológico, consultó en 2020 por aumento del antígeno prostático específico: 4.49 ng/ml, asociado a tacto rectal normal y una resonancia multiparamétrica de próstata mostró una lesión indeterminada. Se realizó una biopsia prostática transperineal por fusión guiado por ecografía. Los análisis preoperatorios, incluido coagulograma, eran normales. No se registraron complicaciones intraquirúrgicas y se indicó el alta. Horas más tarde, consultó al hospital por hipotensión ortostática y dolor abdominal difuso. Los análisis demostraron caída del hematocrito y hemoglobina. Una ecografía y posterior tomografía computada evidenciaron una colección supravesical de 104 × 86mm sin signos de sangrado activo. Se indicó internación en sala de cuidados intensivos debido a hipotensión refractaria a expansiones con requerimiento de vasopresores. Recibió una transfusión de glóbulos rojos. Por favorable evolución, 48 horas después del ingreso recibió el alta. En este caso, fue posible un manejo conservador, sin requerimiento de cirugía o embolización. Si bien no se encontró sitio exacto del sangrado, creemos que la resección transuretral previa podría haber generado cambios anatómicos que facilitaran el pasaje de sangre, posiblemente proveniente de ramas de la arteria vesical inferior a cavidad abdominal luego de la punción.

Improving prostate biopsy decision making in Mexican patients: Still a major public health concern.

BACKGROUND: Prostate cancer screening has reduced its mortality in 21%. However, this has also led to an increased number of biopsies in order to establish the diagnosis, many of them unnecessary. Current screening guidelines prioritize use of prostatic magnetic resonance and new biomarkers to reduce unnecessary biopsies, however, their implementation in developing countries screening programs is mainly limited by its costs. OBJECTIVE: We aimed to evaluate Prostate Biopsy Risk Collaborative Group (PBCG) and Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) 2.0 predictions accuracy in Mexican patients in order to guide prostate biopsy decision making and reduce unnecessary biopsies. MATERIALS AND METHODS: We retrospectively analyzed patients between 55 and 90 years old who underwent prostate biopsy in a high-volume center in Mexico between January 2017 and June 2020. Clinical utility of PBCG and PCPTRC 2.0 to predict high-grade prostate cancer (HGPCa) biopsy outcomes was evaluated using decision curve analysis and compared to actual biopsy decision making. Receiver operating characteristics area under the curve (AUC) was used to measure discrimination and external validation. RESULTS: From 687 patients eligible for prostate biopsy, 433 met selections criteria. One hundred and thirty-five (31.17%) patients were diagnosed with HGPCa, 63 (14.54%) with low-grade disease and 235 (54.27%) had a negative biopsy. PCPTRC 2.0 ≥15% threshold got a standardized net benefit (sNB) of 0.70, while PBCG ≥30% and ≥35% had a sNB of 0.27 and 0.15, respectively. Use of both models for guiding prostate biopsy decision resulted in no statistical difference for HGCPa detection rates, while achieved a significant difference in reducing total and unnecessary biopsies. However, this difference was lower (better) for PCPTRC 2.0, being statistically significative when compared against PBCG thresholds. Both models were well calibrated (AUC 0.79) and achieved external validation compared with international cohorts. CONCLUSIONS: Our study is the first to effectively validate both PCPTRC 2.0 and PBCG predictions for the Mexican population, proving that their use in daily practice improves biopsy decision making by accurately predicting HGPCa and limit unnecessary biopsies without representing additional costs to screening programs.

Differences in negative predictive value of prostate MRI based in men with suspected or known cancer.

OBJECTIVE: To compare the negative predictive value (NPV) of multiparametric MRI for Gleason score (GS) ≥ 3+4 cancer and evaluate predictors of these tumors in men with suspected disease and under active surveillance (AS). MATERIALS AND METHODS: This retrospective study included 38 men with suspected prostate cancer and 38 under AS with scans assigned PI-RADS v2 scores 1 or 2 between May 2016 and September 2017. Biopsy results were no cancer, GS = 3+3, or GS ≥ 3+4. Pre-MRI PSA, gland volume, and PSA density were recorded. Chi-square, equality of proportions, and logistic regressions were used to analyze the data. RESULTS: Intermediate to high-grade cancer was found in 12.8% (95% CI = 2.3-23.3) and 35.9% (95% CI = 20.8-50.9) of men with suspected cancer, and under AS (p = 0.02), respectively. The NPV for GS ≥ 3+4 were 87.2% (suspected cancer; 76.7-97.7) and 64.1% (AS; 49.0-79.2). In neither group PSA significantly predicted cancer grade (p = 0.75 and 0.63). Although it did not reach conventional statistical significance, PSA density was a good predictor of cancer grade in men with suspected disease (p = 0.06), but not under AS (p = 0.62). CONCLUSION: The NPV of multiparametric MRI for GS ≥ 3+4 is higher in men with suspected prostate cancer than in men under AS. PSA density ≤ 0.15 improved the prediction of intermediate to high-grade disease in patients without known cancer.

OBJETIVO: Comparar o valor preditivo negativo (VPN) da RM multiparamétrica da próstata para o diagnóstico de tumores escore de Gleason (EG) ≥ 3+4 e avaliar os preditores desses tumores em homens com suspeita de doença e nos sob vigilância ativa (VA). MATERIAIS E MÉTODOS: Este estudo retrospectivo incluiu 38 homens com suspeita de câncer de próstata e 38 em VA com RM, aos quais foram atribuídos escores PI-RADS v2 1 ou 2 entre maio de 2016 e setembro de 2017. Os resultados da biópsia foram ausência de câncer, câncer EG = 3+3 ou câncer EG ≥ 3+4. PSA pré-RM, volume da glândula e densidade de PSA foram anotados. Qui-quadrado, igualdade de proporções e regressões logísticas foram utilizados para analisar os dados. RESULTADOS: Câncer de grau intermediário a alto grau foi encontrado em 12,8% (IC 95% = 2,3­23,3) e 35,9% (IC 95% = 20,8­50,9) dos homens com suspeita de câncer e nos sob VA (p = 0,02), respectivamente. O VPN para GS ≥ 3+4 foi 87,2% (suspeita de câncer; IC 95% = 76,7­97,7) e 64,1% (VA; IC 95% = 49,0­79,2). Em nenhum dos grupos o PSA previu significativamente o grau de câncer (p = 0,75 e 0,63. Embora não tenha alcançado o limiar de significância estatística usual, a densidade de PSA foi um bom preditor de grau de câncer em homens com suspeita de doença (p = 0,06), mas não sob VA (p = 0,62). CONCLUSÃO: O VPN da RM multiparamétrica para GS ≥ 3+4 é maior em homens com suspeita de câncer de próstata do que em homens sob VA. Uma densidade de PSA ≤ 0,15 melhorou a previsão de doença de grau intermediário a alto grau em pacientes sem diagnóstico prévio de câncer.

Differences in negative predictive value of prostate MRI based in men with suspected or known cancer / Diferenças no valor preditivo negativo da ressonância magnética da próstata baseada em homens com câncer suspeito ou conhecido

Abstract Objective: To compare the negative predictive value (NPV) of multiparametric MRI for Gleason score (GS) ≥ 3+4 cancer and evaluate predictors of these tumors in men with suspected disease and under active surveillance (AS). Materials and Methods: This retrospective study included 38 men with suspected prostate cancer and 38 under AS with scans assigned PI-RADS v2 scores 1 or 2 between May 2016 and September 2017. Biopsy results were no cancer, GS = 3+3, or GS ≥ 3+4. Pre-MRI PSA, gland volume, and PSA density were recorded. Chi-square, equality of proportions, and logistic regressions were used to analyze the data. Results: Intermediate to high-grade cancer was found in 12.8% (95% CI = 2.3-23.3) and 35.9% (95% CI = 20.8-50.9) of men with suspected cancer, and under AS (p = 0.02), respectively. The NPV for GS ≥ 3+4 were 87.2% (suspected cancer; 76.7-97.7) and 64.1% (AS; 49.0-79.2). In neither group PSA significantly predicted cancer grade (p = 0.75 and 0.63). Although it did not reach conventional statistical significance, PSA density was a good predictor of cancer grade in men with suspected disease (p = 0.06), but not under AS (p = 0.62). Conclusion: The NPV of multiparametric MRI for GS ≥ 3+4 is higher in men with suspected prostate cancer than in men under AS. PSA density ≤ 0.15 improved the prediction of intermediate to high-grade disease in patients without known cancer.

Resumo Objetivo: Comparar o valor preditivo negativo (VPN) da RM multiparamétrica da próstata para o diagnóstico de tumores escore de Gleason (EG) ≥ 3+4 e avaliar os preditores desses tumores em homens com suspeita de doença e nos sob vigilância ativa (VA). Materiais e Métodos: Este estudo retrospectivo incluiu 38 homens com suspeita de câncer de próstata e 38 em VA com RM, aos quais foram atribuídos escores PI-RADS v2 1 ou 2 entre maio de 2016 e setembro de 2017. Os resultados da biópsia foram ausência de câncer, câncer EG = 3+3 ou câncer EG ≥ 3+4. PSA pré-RM, volume da glândula e densidade de PSA foram anotados. Qui-quadrado, igualdade de proporções e regressões logísticas foram utilizados para analisar os dados. Resultados: Câncer de grau intermediário a alto grau foi encontrado em 12,8% (IC 95% = 2,3-23,3) e 35,9% (IC 95% = 20,8-50,9) dos homens com suspeita de câncer e nos sob VA (p = 0,02), respectivamente. O VPN para GS ≥ 3+4 foi 87,2% (suspeita de câncer; IC 95% = 76,7-97,7) e 64,1% (VA; IC 95% = 49,0-79,2). Em nenhum dos grupos o PSA previu significativamente o grau de câncer (p = 0,75 e 0,63. Embora não tenha alcançado o limiar de significância estatística usual, a densidade de PSA foi um bom preditor de grau de câncer em homens com suspeita de doença (p = 0,06), mas não sob VA (p = 0,62). Conclusão: O VPN da RM multiparamétrica para GS ≥ 3+4 é maior em homens com suspeita de câncer de próstata do que em homens sob VA. Uma densidade de PSA ≤ 0,15 melhorou a previsão de doença de grau intermediário a alto grau em pacientes sem diagnóstico prévio de câncer.

Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study.

BACKGROUND: There are no comparative data on pathological predictors at diagnosis, between African Caribbean and Caucasian men with prostate cancer (PCa), in equal-access centers. The objective of this study was to evaluate the grade groups of an African Caribbean cohort, newly diagnosed with PCa on prostate biopsy, compared with a Caucasian French Metropolitan cohort. METHODS: A retrospective, a comparative study was conducted between 2008 and 2016 between the University Hospital of Martinique in the French Caribbean West Indies, and the Saint Joseph Hospital in Paris. Clinical, biological, and pathological data were collected at diagnosis. The primary outcome was the grade groups for Gleason score; the secondary outcome was the PCa detection rate. Multivariate analysis was performed using linear regression. RESULTS: Of the 1880 consecutive prostate biopsy performed in the African Caribbean cohort, 945 had a diagnosis of PCa (50.3%) and 500 of 945 in the French cohort (33.8%). African Caribbean patients were older (mean 68.5 vs 67.5 years; P = .028), had worse clinical stage (13.2% vs 5.2% cT3-4; P < .001) and higher median prostate-specific antigen (PSA) level (9.23 vs 8.32 ng/mL; P = .019). On univariate analysis, African Caribbean patients had worse pathological grade groups than French patients (P < .001). Nevertheless, after adjustment on age, stage, and PSA, there were no significant differences between the two cohorts (P = .903). CONCLUSION: African Caribbean patients presented higher PCa detection rate, and higher grade groups at diagnosis than French patients in equal-access centers on univariate analysis but not on multivariate analysis. African Caribbean patients with equivalent clinical and biological characteristics than Caucasian patients at diagnosis might expect the same prognosis for PCa.

Papel actual de la biopsia prostática guiada por ultrasonido en el diagnóstico de cáncer de próstota / Real paper of ultrasound-guided prostatic biopsy in the diagnosis of prostate cancer

El cáncer de próstata representa un serio problema de salud pública. La biopsia prostática constituye la herramienta para determinar su existencia. Objetivo: evaluar la utilidad actual de la biopsia prostática ecoguiada por vía transrectal en el diagnóstico de cáncer de próstata. Métodos: Se revisaron las biopsias de próstata doble sextante realizadas ecoguiadas por vía transrectal en el Hospital Universitario de Caracas en un período de 6 años. Resultados: El número total de biopsias revisadas fue de 2105. El porcentaje de biopsias positivas para malignidad fue de 29,12 %; y la cantidad de lesiones premalignas fue de 9,21 %. El Puntaje de Gleason más frecuentemente diagnosticado fue Gleason 7 (4+3) con un 30,34 %. La correlación biopsia preoperatoria y pieza de prostatectomía fue de 48 %. Conclusiones: La biopsia de próstata ecoguiada doble sextante nos permite de una forma sencilla y eficaz el diagnóstico inicial de cáncer de próstata significativo(AU)

Prostate cancer represents a serious public health problem. Prostate biopsy is the tool to determine its existence. Objective: to evaluate the current utility of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Methods: Sextant double-sided prostate biopsies performed transrectal ultrasound were examined at the Hospital Universitario of Caracas in a period of 6 years. Results: The total number of biopsies reviewed was 2105. The percentage of positive biopsies for malignancy was 29.12 %; and the number of premalignant lesions was 9.21 %. The most frequently diagnosed Gleason score was Gleason 7 (4 + 3) with 30.34 %. Preoperative biopsy and prostatectomy specimen correlation was 48 %. Conclusions: The double-sextant ecoguided prostate biopsy allows us, in a simple and effective way, the initial diagnosis of significant prostate cancer(AU)

Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.

INTRODUCTION: The common tool for diagnosing prostate cancer is prostate-specific antigen (PSA), but the high sensitivity and low specificity of PSA testing are the problems in clinical practice. There are no proper guidelines to investigate the suspected prostate cancer in the Cayman Islands. We correlated PSA levels with the incidence of prostate cancers by tissue diagnosis and proposed logical protocol for prostate screening by using PSA test in this small population. MATERIALS AND METHODS: A total of 165 Afro Caribbean individuals who had prostate biopsy done after the investigations for PSA levels from year 2005 to 2015 were studied retrospectively. The patients were divided into subgroups by baseline PSA levels as follows: <4, 4.1-10, 10.1-20, 20.1-50, 50.1-100, and >100 ng/mL and were correlated to the age and presence of cancer. RESULTS AND DISCUSSION: Benign lesions had lower PSA levels compared to cancer which generally had higher values. Only three cases that had less than 4 ng/mg were turned out to be malignant. When PSA value was more than 100 ng/mL, all the cases were malignant. Between PSA values of 4-100 ng/mL, the probability of cancer diagnosis was 56.71% (76 cancers out of 134 in this range). Limitation of PSA testing has the risk of over diagnosis and the resultant negative biopsies owing to poor specificity. Whereas the cutoff limit for cancer diagnosis still remains 4 ng/mL from our study, most of the patients can be assured of benign lesion below this level and thus morbidity associated with the biopsy can be prevented. When the PSA value is greater than 100 ng, biopsy procedure was mandatory as there were 100% cancers above this level. On the background of vast literature linking PSA to prostate cancer and its difficulty in implementing in clinical practice, we studied literature of this conflicting and complex topic and tried to bring relevant protocols to the small population of Cayman Islands for the screening of prostate cancer. In this study, a total of 165 Afro Caribbean individuals who had prostate biopsy done after the investigations for PSA levels from year 2005 to 2015 were studied retrospectively. As a result of this research work, it can be concluded that a benign diagnosis can be given with a fair certainty when the PSA was below 4 ng/mL and a level of 100 ng/mL can be very unfavorable for the patients. This study helped to solidify the cancer screening protocols in Cayman Islands. CONCLUSION: The PSA level can reassure and educate the patients towards the diagnosis of cancer of prostate in Cayman Islands. Benign diagnosis can be given with a fair certainty when the PSA was below 4 ng/mL and a level of 100 ng/mL can be very unfavorable for the patients. This study helped to solidify the cancer screening protocols in Cayman.

Pre-biopsy MRI as an adjunct for cancer detection in men with elevated PSA and no previous biopsy.

The role of magnetic resonance imaging (MRI) prior to biopsy in the diagnosis of prostate cancer in biopsy-naïve patients has been strengthened by recent developments such as the PIRADS V2 criteria, which cover acquisition, interpretation, and reporting for clinical practice and data collection for research. Important questions on the role of prostate MRI remain: can MRI be used as a triage test before first biopsy series? Can it be used to avoid the use of systematic biopsies (SB) and instead use only targeted biopsies (TB) to MRI-suspicious lesions? Studies to evaluate image guided TB compared to SB have started to accumulate. Objectives of these studies should be to reduce the detection of clinically insignificant disease, to maximize the detection of clinically significant cancer (CSC), to better assess disease size, grade and location. Accurate diagnosis will allow the choice of the most appropriate treatments options, minimising side effects and reducing overtreatment. Study results on MRI-TB detection rates are promising however some limitations should be considered. The majority of published and ongoing studies have been performed at expert centres, in order to demonstrate the optimal performance of MRI. Then, the validation of this strategy in less specialised institutions will be necessary before incorporating recommendations in international guidelines. It necessitates training for radiologists and urologists to perform and read MRI and MRI-targeted biopsy through education programs and standardization tools. All these advances will be consolidated with expected genetic screening tools to improve the detection of aggressive cancer.

Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.

OBJECTIVE: To evaluate the role of multiparametric magnetic resonance imaging (mpMRI) of the prostate and transrectal ultrasonography guided biopsy (TRUS-Bx) with visual estimation in early risk stratification of patients with prostate cancer on active surveillance (AS). PATIENTS AND METHODS: Patients with low-risk, low-grade, localised prostate cancer were prospectively enrolled and submitted to a 3-T 16-channel cardiac surface coil mpMRI of the prostate and confirmatory biopsy (CBx), which included a standard biopsy (SBx) and visual estimation-guided TRUS-Bx. Cancer-suspicious regions were defined using Prostate Imaging Reporting and Data System (PI-RADS) scores. Reclassification occurred if CBx confirmed the presence of a Gleason score ≥7, greater than three positive fragments, or ≥50% involvement of any core. The performance of mpMRI for the prediction of CBx results was assessed. Univariate and multivariate logistic regressions were performed to study relationships between age, prostate-specific antigen (PSA) level, PSA density (PSAD), number of positive cores in the initial biopsy, and mpMRI grade on CBx reclassification. Our report is consistent with the Standards of Reporting for MRI-targeted Biopsy Studies (START) guidelines. RESULTS: In all, 105 patients were available for analysis in the study. From this cohort, 42 (40%) had PI-RADS 1, 2, or 3 lesions and 63 (60%) had only grade 4 or 5 lesions. Overall, 87 patients underwent visual estimation TRUS-Bx. Reclassification among patients with PI-RADS 1, 2, 3, 4, and 5 was 0%, 23.1%, 9.1%, 74.5%, and 100%, respectively. Overall, mpMRI sensitivity, specificity, positive predictive value, and negative predictive value for disease reclassification were 92.5%, 76%, 81%, and 90.5%, respectively. In the multivariate analysis, only PSAD and mpMRI remained significant for reclassification (P < 0.05). In the cross-tabulation, SBx would have missed 15 significant cases detected by targeted biopsy, but SBx did detect five cases of significant cancer not detected by targeted biopsy alone. CONCLUSION: Multiparametric magnetic resonance imaging is a significant tool for predicting cancer severity reclassification on CBx among AS candidates. The reclassification rate on CBx is particularly high in the group of patients who have PI-RADS grades 4 or 5 lesions. Despite the usefulness of visual-guided biopsy, it still remains highly recommended to retrieve standard fragments during CBx in order to avoid missing significant tumours.

Effect on hemostasis of an absorbable hemostatic gelatin sponge after transrectal prostate needle biopsy

Objectives To examine the usefulness of an absorbable hemostatic gelatin sponge for hemostasis after transrectal prostate needle biopsy. Subjects and Methods The subjects comprised 278 participants who underwent transrectal prostate needle biopsy. They were randomly allocated to the gelatin sponge insertion group (group A: 148 participants) and to the non-insertion group (group B: 130 participants). In group A, the gelatin sponge was inserted into the rectum immediately after biopsy. A biopsy-induced hemorrhage was defined as a case in which a subject complained of bleeding from the rectum, and excretion of blood clots was confirmed. A blood test was performed before and after biopsy, and a questionnaire survey was given after the biopsy. Results Significantly fewer participants in group A required hemostasis after biopsy compared to group B (3 (2.0%) vs. 11 (8.5%), P=0.029). The results of the blood tests and the responses from the questionnaire did not differ significantly between the two groups. In multivariate analysis, only “insertion of a gelatin sponge into the rectum” emerged as a significant predictor of hemostasis. Conclusion Insertion of a gelatin sponge into the rectum after transrectal prostate needle biopsy significantly increases hemostasis without increasing patient symptoms, such as pain and a sense of discomfort. .

Impacto del uso de antibióticos en el valor de PSA, previo a la biopsia de prostata / Impact of antibiotic use in prostate-specific antigen levels before prostate biopsy

Existen observaciones clínicas sobre el uso empírico de antibióticos en pacientes con alto nivel de PSA, sin síntomas de infecciones del tracto urinario y con indicación de biopsia prostática. El uso indiscriminado de antibióticos puede llevar a la resistencia bacteriana y diversos efectos secundarios; pero sobre todo, esto puede ser una acción médica injustificada. El objetivo de esta investigación es determinar el impacto del uso de antibióticos en los valores de PSA antes de la biopsia prostática y en la decisión de si hacer o no una biopsia prostática en pacientes con sospecha de neoplasia prostática. Estudio de casos y controles de 63 pacientes menores de 80 años de edad, con tacto rectal normal, sin infección urinaria y los valores de PSA alterado con indicación de biopsia. El grupo de control no recibió medicamento y el grupo de casos recibió cotrimoxazol (80/400 mg) cada 12 horas durante 10 días. Quince días más tarde los niveles de PSA se evaluaron de nuevo y los resultados se analizaron estadísticamente. No se encontraron diferencias significativas entre ambos grupos en relación con la edad, tacto rectal o el valor de PSA. La variación de la PSA después del uso de la terapia con antibióticos no fue significativa (p = 0,588). El uso de la terapia antimicrobiana para disminuir los valores de PSA antes de una biopsia de próstata es controvertido y no hay evidencia científica para el tratamiento de una prostatitis asintomática que pueden estar alterando los valores de PSA. Los resultados de nuestro estudio muestran la necesidad de una investigación más compleja que puede confirmar que la terapia antimicrobiana no tiene un papel terapéutico en esta situación específica y común...

There is a clinical observation about the empiric use of antibiotics on patients with high PSA level, without symptoms of urinary tract infections and with indication for prostatic biopsy. The indiscriminate use of antibiotics may lead to bacterial resistance and various others side effects as well; but above all, this may be an unjustified medical action. The objective of this research is to determinate the impact of antibiotic use on PSA values before prostatic biopsy and on the decision whether make or not a prostatic biopsy in patients suspected of having prostatic cancer. Case and control study of 63 patients younger than 80 years old, with normal rectal tact, without symptoms of urinary tract infection and PSA values altered with biopsy indication. Control group did not receive medicament and the case group received Cotrimoxazole (80/400 mg) every 12 hours for 10 days. 15 days later PSA levels were evaluated again and the results were statistically analyzed. No significant differences were found between both groups in relation to age or PSA value. The variation of the PSA after the use of antibiotic therapy was no significant (p=0,588). The use of antimicrobial therapy to decrease the values of PSA before a prostate biopsy is controversial and there isn’t scientific evidence to treat a possible asyntomatic prostatitis that may be altering the PSA values. The results of our study shows the need of a more complex research that can confirm that the antimicrobial therapy has no therapeutic role on this specific and common situation...

Prostate Stromal Tumor of Uncertain Malignant Potential: Case Report With 5-Year Follow-up.

Prostate stromal tumor of uncertain malignant potential is a term used to describe a specialized proliferation of stromal cells within the prostate. Most of these tumors tend to be benign, but some can present with local invasion or progress to prostatic stromal sarcoma with distant metastasis. We report a case of a 62-year-old male patient who presented to us with a diagnosis of stromal tumor of uncertain malignant potential. We have followed up the patient for 5 years with imaging, prostate-specific antigen checks, and annual prostate biopsies.

Ecografía y biopsia prostéticas en la detección del carcinoma prostético / Prostate ultrasound and biopsy in the detection of prostate carcinoma

Objetivo: Mostrar nuestra experiencia en ecografía prostática transrectal y biopsia prostática bajo guía ecográfica a lo largo de 10 años, a través de la realización de un análisis retrospectivo, con el fin de evaluar sus beneficios en la detección del adenocarcinoma, identificar la distribución de muestras positivas en la glándula y exponer la utilidad de la punción de imágenes nodulares. prostáticas transrectales seguidas de biopsias prostáticas bajo control ecográfico. En la muestra se incluyó a pacientes que se realizaron más de una biopsia. Los datos obtenidos de estos procedimientos permitieron identificar la presencia de tres grupos etarios de acuerdo a la incidencia de la patología, conocer la localización más frecuente del adenocarcinoma dentro de la próstata y evaluar la utilidad de la biopsia de los nódulos prostáticos en la detección del adenocarcinoma. Resultados: El análisis de la muestra arrojó un porcentaje de detección del adenocarcinoma del 16% en los menores de 50 años, del 36% en aquellos entre los 50 y 60 años, y del 48% en los mayores de 65 años. La base izquierda de la próstata fue la localización con el índice más alto de positividad (15%), seguido por la media izquierda (14%), la base derecha (14%), la media derecha (13%), el ápex izquierdo (12%), el medio lateral izquierdo (12%), el ápex derecho (11%) y el medio lateral derecho (10%). Doscientos noventa y nueve pacientes presentaron imágenes nodulares: 118 (Grupo A) tuvieron alguna muestra positiva y 181 presentaron resultados negativos (Grupo B). A su vez, el Grupo A se dividió en 3 subgrupos: el Subgrupo A, cuyo resultado positivo se registró en la muestra del nódulo, pero fue negativo en el resto de la glándula; Subgrupo B, cuyos resultados fueron positivos en el resto de la glándula y negativos en la muestra del nódulo; y Subgrupo C, cuyo resultado fue positivo tanto en las muestras de la glándula como en las del nódulo (combinación más frecuente de los tres subgrupos). Conclusión: La ecografía y la biopsia prostáticas bajo guía ecográfi ca juegan un rol importante en la evaluación de la próstata ante la sospecha de un adenocarcinoma. Según nuestra experiencia, la biopsia prostática bajo guía ecográfi ca es el método de mayor utilidad para la detección, especialmente en pacientes mayores de 65 años, y debería incluirse la muestra del nódulo (si la hubiese) en el esquema por octantes.

Purpose: To present our experience in prostatic transrectal ultrasound and transrectal ultrasound-guided biopsy over a ten-year period by a retrospective analysis in order to determine the detection rate of adenocarcinoma, identify the distribution of positive samples in the gland, and evaluate the usefulness of biopsy of nodules seen on imaging studies. Materials and methods: A total of 1163 ultrasound and ultrasound-guided transrectal prostate biopsies were performed between March 2001 and November 2011. The population sample included patients who had more than one biopsy performed. Data obtained from these procedures enables us to identify three age groups according to the incidence of pathology, to determine the most frequent location of adenocarcinoma within the prostate, and to evaluate the usefulness of prostate nodules biopsy in the detection of adenocarcinoma. Results: The data analysis showed a 16% detection rate of adenocarcinoma in men under 50 years of age, 36% in patients between 50 and 65 years, and 48% in patients older than 65 years. The left base of the prostate had the highest detection rate (15%), followed by left medium (14%), right base (14%), right medium (13%), left apex (12%), left lateral medium (12%), right apex (11%) and right lateral medium (10%). Nodular images were found in 299 patients: 118 were positive for adenocarcinoma (Group A) and 181 were negative (Group B). Group A was divided into 3 subgroups: Subgroup A, with a positive result only in the nodule sample, and a negative result in the rest of the gland sample; Subgroup B, with a positive result in the gland samples but negative in the nodule sample; and Subgroup C, with results that were positive both in the gland and nodule samples. Conclusion: Ultrasound and ultrasound-guided transrectal prostate biopsy play an important role in the evaluation of the prostate when adenocarcinoma is suspected. Based on our experience, ultrasound-guided prostate biopsy is the most useful method for the detection of adenocarcinoma, especially in patients older than 65 years of age, and the nodule sample (if any) should be included in the eight-biopsy scheme.

Ecografía y biopsia prostéticas en la detección del carcinoma prostético / Prostate ultrasound and biopsy in the detection of prostate carcinoma

Objetivo: Mostrar nuestra experiencia en ecografía prostática transrectal y biopsia prostática bajo guía ecográfica a lo largo de 10 años, a través de la realización de un análisis retrospectivo, con el fin de evaluar sus beneficios en la detección del adenocarcinoma, identificar la distribución de muestras positivas en la glándula y exponer la utilidad de la punción de imágenes nodulares. prostáticas transrectales seguidas de biopsias prostáticas bajo control ecográfico. En la muestra se incluyó a pacientes que se realizaron más de una biopsia. Los datos obtenidos de estos procedimientos permitieron identificar la presencia de tres grupos etarios de acuerdo a la incidencia de la patología, conocer la localización más frecuente del adenocarcinoma dentro de la próstata y evaluar la utilidad de la biopsia de los nódulos prostáticos en la detección del adenocarcinoma. Resultados: El análisis de la muestra arrojó un porcentaje de detección del adenocarcinoma del 16% en los menores de 50 años, del 36% en aquellos entre los 50 y 60 años, y del 48% en los mayores de 65 años. La base izquierda de la próstata fue la localización con el índice más alto de positividad (15%), seguido por la media izquierda (14%), la base derecha (14%), la media derecha (13%), el ápex izquierdo (12%), el medio lateral izquierdo (12%), el ápex derecho (11%) y el medio lateral derecho (10%). Doscientos noventa y nueve pacientes presentaron imágenes nodulares: 118 (Grupo A) tuvieron alguna muestra positiva y 181 presentaron resultados negativos (Grupo B). A su vez, el Grupo A se dividió en 3 subgrupos: el Subgrupo A, cuyo resultado positivo se registró en la muestra del nódulo, pero fue negativo en el resto de la glándula; Subgrupo B, cuyos resultados fueron positivos en el resto de la glándula y negativos en la muestra del nódulo; y Subgrupo C, cuyo resultado fue positivo tanto en las muestras de la glándula como en las del nódulo (combinación más frecuente de los tres subgrupos). Conclusión: La ecografía y la biopsia prostáticas bajo guía ecográfi ca juegan un rol importante en la evaluación de la próstata ante la sospecha de un adenocarcinoma. Según nuestra experiencia, la biopsia prostática bajo guía ecográfi ca es el método de mayor utilidad para la detección, especialmente en pacientes mayores de 65 años, y debería incluirse la muestra del nódulo (si la hubiese) en el esquema por octantes.(AU)

Purpose: To present our experience in prostatic transrectal ultrasound and transrectal ultrasound-guided biopsy over a ten-year period by a retrospective analysis in order to determine the detection rate of adenocarcinoma, identify the distribution of positive samples in the gland, and evaluate the usefulness of biopsy of nodules seen on imaging studies. Materials and methods: A total of 1163 ultrasound and ultrasound-guided transrectal prostate biopsies were performed between March 2001 and November 2011. The population sample included patients who had more than one biopsy performed. Data obtained from these procedures enables us to identify three age groups according to the incidence of pathology, to determine the most frequent location of adenocarcinoma within the prostate, and to evaluate the usefulness of prostate nodules biopsy in the detection of adenocarcinoma. Results: The data analysis showed a 16% detection rate of adenocarcinoma in men under 50 years of age, 36% in patients between 50 and 65 years, and 48% in patients older than 65 years. The left base of the prostate had the highest detection rate (15%), followed by left medium (14%), right base (14%), right medium (13%), left apex (12%), left lateral medium (12%), right apex (11%) and right lateral medium (10%). Nodular images were found in 299 patients: 118 were positive for adenocarcinoma (Group A) and 181 were negative (Group B). Group A was divided into 3 subgroups: Subgroup A, with a positive result only in the nodule sample, and a negative result in the rest of the gland sample; Subgroup B, with a positive result in the gland samples but negative in the nodule sample; and Subgroup C, with results that were positive both in the gland and nodule samples. Conclusion: Ultrasound and ultrasound-guided transrectal prostate biopsy play an important role in the evaluation of the prostate when adenocarcinoma is suspected. Based on our experience, ultrasound-guided prostate biopsy is the most useful method for the detection of adenocarcinoma, especially in patients older than 65 years of age, and the nodule sample (if any) should be included in the eight-biopsy scheme.(AU)

Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens

OBJECTIVE: To evaluate the concordance between the Gleason scores of prostate biopsies and radical prostatectomy specimens, thereby highlighting the importance of the prostate-specific antigen (PSA) level as a predictive factor of concordance. METHODS: We retrospectively analyzed 253 radical prostatectomy cases performed between 2006 and 2011. The patients were divided into 4 groups for the data analysis and dichotomized according to the preoperative PSA, <10 ng/mL and ≥10 ng/mL. A p-score <0.05 was considered significant. RESULTS: The average patient age was 63.3±7.8 years. The median PSA level was 9.3±4.9 ng/mL. The overall concordance between the Gleason scores was 52%. Patients presented preoperative PSA levels <10 ng/mL in 153 of 235 cases (65%) and ≥10 ng/mL in 82 of 235 cases (35%). The Gleason scores were identical in 86 of 153 cases (56%) in the <10 ng/mL group and 36 of 82 (44%) cases in the ≥10 ng/mL group (p = 0.017). The biopsy underestimated the Gleason score in 45 (30%) patients in the <10 ng/mL group and 38 (46%) patients in the ≥10 ng/mL (p = 0.243). Specifically, the patients with Gleason 3 + 3 scores according to the biopsies demonstrated global concordance in 56 of 110 cases (51%). In this group, the patients with preoperative PSA levels <10 ng/dL had higher concordance than those with preoperative PSA levels ≥10 ng/dL (61% x 23%, p = 0.023), which resulted in 77% upgrading after surgery in those patients with PSA levels ≥10 ng/dl. CONCLUSION: The Gleason scores of needle prostate biopsies and those of the surgical specimens were concordant in approximately half of the global sample. The preoperative PSA level was a strong predictor of discrepancy and might improve the identification of those patients who tended to be upgraded after surgery, particularly ...

Caracterización de parámetros clínicos y anatomopatológicos de pacientes con cáncer de próstata localmente avanzado en Hospital Barros Luco Trudeau / Characterization of clinical and pathological parameters of patients with locally advanced prostate cancer in Hospital Barros Luco Trudeaus

La estadificación clínica del Cáncer de Próstata es una evaluación de la extensión de la enfermedad mediante el uso de parámetros previos al tratamiento como tacto rectal, PSA, biopsia transrectal e imágenes radiológicas. El estadío anatomo patológico post quirúrgico comprende el análisis histopatológico de la pieza operatoria, lo que constituye una estimación más precisa de la extensión de la enfermedad y representa el método más ¬ fiable para predecir el resultado del tratamiento. De 386 pacientes sometidos a Prostatectomía entre los años 2002 y 2012 se realiza estudio retrospectivo de 48 pacientes, que presentaron compromiso extra prostático. Análisis estadístico de las variables estudiadas mediante prueba de Chi cuadrado. De 386 pacientes sometidos a Prostatectomía, el 12,4 por ciento presentó compromiso extra prostático. La edad promedio fue de 64,1 años; el PSA promedio 12,2 ng/ml. El 37,77 por ciento presentaba un tacto rectal sospechoso. El tamaño prostático promedio estimado por ecografía fue 38,2 cc. La biopsia defi¬nitiva reveló un volumen glandular promedio de 64 cc. y volumen tumoral promedio de 6,9 cc. El 72,92 por ciento fue clasi¬ficado con un score de Gleason 7. El 82 por ciento presentaba compromiso glandular bilateral. El 65,12 por ciento presentó compromiso capsular; 73,9 por ciento compromiso de bordes quirúrgicos; 23,4 por ciento compromiso unilateral y 19,1 por ciento bilateral de vesículas seminales. No fue posible establecer evidencia que permita afirmar la existencia de algún factor predictor para el compromiso capsular, de bordes quirúrgicos, de vesículas seminales, de conductos deferentes, ni permeación linfática. Se logró establecer una relación estadísticamente significativa entre niveles de PSA y probabilidad de compromiso vascular.

Clinical staging of prostate cancer is an assessment of the extent of disease by using pretreatment parameters as DRE, PSA, transrectal biopsy and scans. The postoperative pathologic stage comprises histopathological analysis of surgical piece, which is a more accurate estimate of the extent of disease and represents the most reliable method to predict the outcome of treatment. Retrospective study of 48 patients with prostate cancer who underwent radical prostatectomy between 2002 and 2012, which showed extraprostatic commitment. Statistical analysis of the variables using chi-square test. Of 386 patients undergoing prostatectomy, 12.4 percent had extraprostatic commitment. The average age was 64.1 years and the mean PSA 12.2 ng / ml. The 37.77 percent had a suspicious DRE. The average prostate size estimated by ultrasound was 38.2 cc. The ¬ final biopsy revealed an average volume of 64 cc glandular. and average tumor volume of 6.9 cc. The 72.92 percent was classified with a Gleason score 7. 82 percent had bilateral glandular involvement. The capsular involvement showed 65.12 percent, 73.9 percent commitment surgical margins, 23.4 percent and 19.1 percent unilateral commitment bilateral seminal vesicles. It was not possible to establish evidence to a rm the existence of a predictor factor for capsular involvement of surgical margins, seminal vesicle, vas deferens, or lymphatic permeation. They managed to establish a statistically significant relationship between PSA levels and probability of vascular compromise.